Actualités

Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which trade-off actually serves income investors better after both companies reported earnings?

Second-quarter earnings season shook loose some rare discounts on five high-yield dividend stocks that Wall Street analysts still rate as Buys, and income-focused investors may not get another shot at these prices.

Few big-pharma bosses enjoy a stronger reputation on Wall Street than AstraZeneca’s chief executive, Pascal Soriot. After plunging on a Financial Times report of merger discussions with Bristol-Myers Squibb shares of AstraZeneca recovered somewhat when Reuters reported there are no ongoing talks. After rebuffing Pfizer’s $120 billion takeover bid in 2014, he steadily transformed AstraZeneca into one of the drug industry’s top growth stories.

Pfizer (PFE) is back in focus after its second quarter 2026 update, which paired a reported net loss and sizeable non cash impairments with higher full year revenue guidance and solid non COVID product performance. See our latest analysis for Pfizer. The latest results and raised revenue guidance have lifted sentiment toward Pfizer, with the stock showing a 1 month share price return of 8.81% and a 1 year total shareholder return of 15.42%, although longer term total shareholder returns...

The market is pricing in an unusually high cash-generation yield for one of the world's largest drugmakers, forcing investors to decide if the price reflects a temporary problem or a permanent decline.

Don't let their recent poor performances chase you away.

Pfizer increased its savings target and revenue outlook, but investors remained focused on patent expirations and pipeline execution.

PFE raises its 2026 revenue outlook as non-COVID growth, deeper cost cuts and pipeline catalysts offset weaker COVID demand.

Pfizer (NYSE:PFE) reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue increased 1% operationally from a year earlier, while revenue excluding COVID-19 products rose 5% o

Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

Companies In The News Are: ALSN, CLX, AEIS, PFE.

IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.

Moby summary of Pfizer Inc.'s Q2 2026 earnings call

The quarter exposed where Pfizer's recovery is really coming from

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.7% and th

The healthcare giant showered its owners with cash, yet the stock fell behind. Here is the accounting of what investors actually got and what the trade-off cost them.

Fuelled by blockbusters such as Eliquis, Pfizer is cementing its post-Covid revenue legacy.

Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.

Pfizer lifted its 2026 revenue forecast by $500 million at the midpoint.

Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both ph

Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported...

Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.

Pfizer (NYSE:PFE) increased the lower end of its full-year revenue guidance after reporting second-quarter 2026 results that exceeded Wall Street expectations, supported by robust sales of its blood thinner Eliquis. The pharmaceutical company also reaffirmed its earnings outlook for the year, while its shares moved higher in U.

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pfizer stock inched higher early Tuesday on a solid second-quarter report that included a sales guidance boost.

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15.03 billion. The company expects the full year’s revenue to be around $61.5 billion, close to analysts’ estimates. Its non-GAAP profit of $0.77 per share was 12.9% above analysts’ consensus estimates.

Rising sales of drugs for cancer and heart disease helped offset steep declines for Pfizer’s Covid-19 products.

Pfizer (NYSE:PFE) reported positive Phase 3 results for LITFULO in nonsegmental vitiligo. The company plans to pursue global regulatory filings for LITFULO as an oral therapy for this autoimmune skin disease. For investors watching Pfizer, this update highlights an area of its late stage pipeline that sits outside its COVID and oncology businesses. Nonsegmental vitiligo is a chronic condition with limited systemic treatment options, so additional clinical data around efficacy and safety is...

Pfizer faces $17 billion patent cliff as investors brace for earnings

Pfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?